Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status

Authors: Annika Gustafsson Asting, Helena Carén, Marianne Andersson, Christina Lönnroth, Kristina Lagerstedt, Kent Lundholm

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Increased cyclooxygenase activity promotes progression of colorectal cancer, but the mechanisms behind COX-2 induction remain elusive. This study was therefore aimed to define external cell signaling and transcription factors relating to high COX-2 expression in colon cancer tissue.

Method

Tumor and normal colon tissue were collected at primary curative operation in 48 unselected patients. COX-2 expression in tumor and normal colon tissue was quantified including microarray analyses on tumor mRNA accounting for high and low tumor COX-2 expression. Cross hybridization was performed between tumor and normal colon tissue. Methylation status of up-stream COX-2 promoter region was evaluated.

Results

Tumors with high COX-2 expression displayed large differences in gene expression compared to normal colon. Numerous genes with altered expression appeared in tumors of high COX-2 expression compared to tumors of low COX-2. COX-2 expression in normal colon was increased in patients with tumors of high COX-2 compared to normal colon from patients with tumors of low COX-2. IL1β, IL6 and iNOS transcripts were up-regulated among external cell signaling factors; nine transcription factors (ATF3, C/EBP, c-Fos, Fos-B, JDP2, JunB, c-Maf, NF-κB, TCF4) showed increased expression and 5 (AP-2, CBP, Elk-1, p53, PEA3) were decreased in tumors with high COX-2. The promoter region of COX-2 gene did not show consistent methylation in tumor or normal colon tissue.

Conclusions

Transcription and external cell signaling factors are altered as covariates to COX-2 expression in colon cancer tissue, but DNA methylation of the COX-2 promoter region was not a significant factor behind COX-2 expression in tumor and normal colon tissue.
Appendix
Available only for authorised users
Literature
1.
Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009, 30 (3): 377-386. 10.1093/carcin/bgp014.CrossRefPubMed
2.
Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, Lonnroth C, Lundholm K: EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer. 2007, 121 (2): 232-240. 10.1002/ijc.22582.CrossRefPubMed
3.
Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Lonnroth C, Lundholm K: Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol. 2007, 1-6.
4.
Cahlin C, Gelin J, Andersson M, Lonnroth C, Lundholm K: The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors. Int J Oncol. 2005, 27 (4): 913-923.PubMed
5.
Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW: Aspirin use and risk of fatal cancer. Cancer Res. 1993, 53 (6): 1322-1327.PubMed
6.
Muscat JE, Stellman SD, Wynder EL: Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer. 1994, 74 (7): 1847-1854. 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-#.CrossRefPubMed
7.
Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, et al: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003, 348 (10): 883-890. 10.1056/NEJMoa021633.CrossRefPubMed
8.
Gelin J, Andersson C, Lundholm K: Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res. 1991, 51 (3): 880-885.PubMed
9.
Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, Korner U, Gulich M, Karrefors I, Norli B, et al: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 1994, 54 (21): 5602-5606.PubMed
10.
Hull MA, Ko SC, Hawcroft G: Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?. Mol Cancer Ther. 2004, 3 (8): 1031-1039.PubMed
11.
Cahlin C, Lonnroth C, Arvidsson A, Nordgren S, Lundholm K: Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol. 2008, 32 (4): 909-918.PubMed
12.
Chun KS, Surh YJ: Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol. 2004, 68 (6): 1089-1100. 10.1016/j.bcp.2004.05.031.CrossRefPubMed
13.
Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN: Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 2006, 38 (10): 1654-1661. 10.1016/j.biocel.2006.03.021.CrossRefPubMed
14.
Han W, Cauchi S, Herman JG, Spivack SD: DNA methylation mapping by tag-modified bisulfite genomic sequencing. Anal Biochem. 2006, 355 (1): 50-61. 10.1016/j.ab.2006.05.010.CrossRefPubMed
15.
Hur K, Song SH, Lee HS, Ho Kim W, Bang YJ, Yang HK: Aberrant methylation of the specific CpG island portion regulates cyclooxygenase-2 gene expression in human gastric carcinomas. Biochem Biophys Res Commun. 2003, 310 (3): 844-851. 10.1016/j.bbrc.2003.09.095.CrossRefPubMed
16.
Tusnady GE, Simon I, Varadi A, Aranyi T: BiSearch: primer-design and search tool for PCR on bisulfite-treated genomes. Nucleic Acids Res. 2005, 33 (1): e9-10.1093/nar/gni012.CrossRefPubMedPubMedCentral
17.
Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T: BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics. 2005, 21 (21): 4067-4068. 10.1093/bioinformatics/bti652.CrossRefPubMed
18.
Cao Y, Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002, 190 (3): 279-286. 10.1002/jcp.10068.CrossRefPubMed
19.
Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K, Nukiwa T: Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 2002, 62 (1): 63-66.PubMed
20.
21.
Zhi H, Wang L, Zhang J, Zhou C, Ding F, Luo A, Wu M, Zhan Q, Liu Z: Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis. 2006, 27 (6): 1214-1221. 10.1093/carcin/bgi304.CrossRefPubMed
22.
Lonnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K, Lundholm K: Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun. 2008, 8: 5-PubMedPubMedCentral
23.
Gustafsson A, Andersson M, Lagerstedt K, Lonnroth C, Nordgren S, Lundholm K: Receptor and enzyme expression for prostanoid metabolism in colorectal cancer related to tumor tissue PGE2. Int J Oncol. 2010, 36 (2): 469-478.PubMed
24.
Ashida R, Tominaga K, Sasaki E, Watanabe T, Fujiwara Y, Oshitani N, Higuchi K, Mitsuyama S, Iwao H, Arakawa T: AP-1 and colorectal cancer. Inflammopharmacology. 2005, 13 (1-3): 113-125. 10.1163/156856005774423935.CrossRefPubMed
25.
Grau R, Iniguez MA, Fresno M: Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism. Cancer Res. 2004, 64 (15): 5162-5171. 10.1158/0008-5472.CAN-04-0849.CrossRefPubMed
26.
Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004, 429 (6990): 457-463. 10.1038/nature02625.CrossRefPubMed
27.
Castells A, Paya A, Alenda C, Rodriguez-Moranta F, Agrelo R, Andreu M, Pinol V, Castellvi-Bel S, Jover R, Llor X, et al: Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency. Clin Cancer Res. 2006, 12 (6): 1686-1692. 10.1158/1078-0432.CCR-05-1581.CrossRefPubMed
28.
Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa JP: Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res. 2000, 60 (15): 4044-4048.PubMed
29.
Kim SP, Park JW, Lee SH, Lim JH, Jang BC, Jang IH, Freund JN, Suh SI, Mun KC, Song DK, et al: Homeodomain protein CDX2 regulates COX-2 expression in colorectal cancer. Biochem Biophys Res Commun. 2004, 315 (1): 93-99. 10.1016/j.bbrc.2004.01.020.CrossRefPubMed
30.
Cressey R, Pimpa S, Tontrong W, Watananupong O, Leartprasertsuke N: Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression. Cancer Lett. 2006, 233 (2): 232-239. 10.1016/j.canlet.2005.03.023.CrossRefPubMed
31.
Denkert C, Koch I, von Keyserlingk N, Noske A, Niesporek S, Dietel M, Weichert W: Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol. 2006, 19 (9): 1261-1269. 10.1038/modpathol.3800645.CrossRefPubMed
32.
Lin DW, Nelson PS: The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma. Clin Prostate Cancer. 2003, 2 (2): 119-126.CrossRefPubMed
33.
Duque J, Diaz-Munoz MD, Fresno M, Iniguez MA: Up-regulation of cyclooxygenase-2 by interleukin-1 beta in colon carcinoma cells. Cell Signal. 2006, 18 (8): 1262-1269. 10.1016/j.cellsig.2005.10.009.CrossRefPubMed
34.
Maihofner C, Charalambous MP, Bhambra U, Lightfoot T, Geisslinger G, Gooderham NJ: Expression of cyclooxygenase-2 parallels expression of interleukin-1 beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis. 2003, 24 (4): 665-671. 10.1093/carcin/bgg006.CrossRefPubMed
35.
Gauthier ML, Pickering CR, Miller CJ, Fordyce CA, Chew KL, Berman HK, Tlsty TD: p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue. Cancer Res. 2005, 65 (5): 1792-1799. 10.1158/0008-5472.CAN-04-3507.CrossRefPubMed
Metadata
Title
COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status
Authors
Annika Gustafsson Asting
Helena Carén
Marianne Andersson
Christina Lönnroth
Kristina Lagerstedt
Kent Lundholm
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-238

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Commentary

Ten years of progress in radiation oncology

Research article

Matched-pair analysis of patients with female and male breast cancer: a comparative analysis

Research article

Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence

Research article

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

Research article

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer

Research article

NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits